Rafael Holdings (RFL) Depreciation & Amortization - Total (2019 - 2023)
Rafael Holdings' (RFL) quarterly Depreciation & Amortization - Total came in at $17000.0 in Q4 2023, down 22.73% year-over-year from $22000.0 in Q4 2022, and down 5.56% quarter-over-quarter from $18000.0 in Q3 2023.
Powered by 
Analysis
Rafael Holdings (RFL) Depreciation & Amortization - Total (2019 - 2023) Analysis & Trends
Rafael Holdings (RFL) has reported Depreciation & Amortization - Total for 5 consecutive years, with $17000.0 the latest figure, recorded in Q4 2023.
- On a quarterly basis, Depreciation & Amortization - Total fell 22.73% year-over-year to $17000.0 in Q4 2023; TTM through Oct 2023 was $73000.0, a 1725.0% increase from a year earlier, with the FY2023 full-year figure at $78000.0, up 7700.0% from the prior year.
- Depreciation & Amortization - Total was $17000.0 for Q4 2023 at Rafael Holdings, down from $18000.0 in the prior quarter.
- Over five years, Depreciation & Amortization - Total peaked at $1.5 million in Q3 2021 and troughed at -$53000.0 in Q3 2022.
- A 5-year average of $314058.8 and a median of $22000.0 in 2022 frame the typical range for Depreciation & Amortization - Total.
- Across the five-year window, Depreciation & Amortization - Total tumbled 103.57% in 2022 and surged 133.96% in 2023, its largest moves.
- Over 5 years, Depreciation & Amortization - Total stood at $500000.0 in 2019, then retreated by 20.0% to $400000.0 in 2020, then slumped by 95.25% to $19000.0 in 2021, then increased by 15.79% to $22000.0 in 2022, then retreated by 22.73% to $17000.0 in 2023.
- The last three Depreciation & Amortization - Total figures came in at $17000.0 (Q4 2023), $18000.0 (Q3 2023), and $19000.0 (Q2 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2023 | 17,000.00 |
| Jul 31, 2023 | 18,000.00 |
| Apr 30, 2023 | 19,000.00 |
| Jan 31, 2023 | 19,000.00 |
| Oct 31, 2022 | 22,000.00 |
| Jul 31, 2022 | -53,000.00 |
| Apr 30, 2022 | 17,000.00 |
| Jan 31, 2022 | 18,000.00 |
| Oct 31, 2021 | 19,000.00 |
| Jul 31, 2021 | 1.48 Mn |
| Apr 30, 2021 | 200,000.00 |
| Jan 31, 2021 | 400,000.00 |
| Oct 31, 2020 | 400,000.00 |
| Jul 31, 2020 | 1.26 Mn |
| Apr 30, 2020 | 500,000.00 |
| Jan 31, 2020 | 500,000.00 |
| Oct 31, 2019 | 500,000.00 |